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Abstract
Background: Circulating progenitor cells (CPC) contribute to the homeostasis of the vessel wall, and a reduced CPC count
predicts cardiovascular morbidity and mortality. We tested the hypothesis that CPC count improves cardiovascular risk
stratification and that this is modulated by low-grade inflammation.
Methodology/Principal Findings: We pooled data from 4 longitudinal studies, including a total of 1,057 patients having
CPC determined and major adverse cardiovascular events (MACE) collected. We recorded cardiovascular risk factors and
high-sensitive C-reactive protein (hsCRP) level. Risk estimates were derived from Cox proportional hazard analyses. CPC
count and/or hsCRP level were added to a reference model including age, sex, cardiovascular risk factors, prevalent CVD,
chronic renal failure (CRF) and medications. The sample was composed of high-risk individuals, as 76.3% had prevalent CVD
and 31.6% had CRF. There were 331 (31.3%) incident MACE during an average 1.761.1 year follow-up time. CPC count was
independently associated with incident MACE even after correction for hsCRP. According to C-statistics, models including
CPC yielded a non-significant improvement in accuracy of MACE prediction. However, the integrated discrimination
improvement index (IDI) showed better performance of models including CPC compared to the reference model and
models including hsCRP in identifying MACE. CPC count also yielded significant net reclassification improvements (NRI) for
CV death, non-fatal AMI and other CV events. The effect of CPC was independent of hsCRP, but there was a significant more-
than-additive interaction between low CPC count and raised hsCRP level in predicting incident MACE.
Conclusions/Significance: In high risk individuals, a reduced CPC count helps identifying more patients at higher risk of
MACE over the short term, especially in combination with a raised hsCRP level.
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Introduction
Cardiovascular disease (CVD) is the leading cause of death in
western countries. Thus, identification of patients at risk for future
CVD must be pursued in order to implement preventive strategies.
Traditional cardiovascular risk factors are commonly used for this
purpose and many risk scores have been proposed based on various
combinations of risk factors. However, a significant number of
cardiovascular events still occur in subjects classified in the low or
intermediate risk categories [1], thus reducing the chance to apply
disease prevention in many subjects who would benefit from it.
Identification of emerging risk factors and novel biomarkers of CVD
has recently gained attention, in an attempt to improve the
performance of risk prediction algorithms. A number of CVD
biomarkers have been identified, many of which are independently
associated with incident cardiovascular events in survival analyses
[2]. However, the usefulness of testing biomarkers in the clinical
setting has been questioned, because there is no definite evidence
that biomarkers, alone or in combination, improve cardiovascular
riskstratificationandidentificationofpatientsatriskforfutureCVD.
Indeed, it is increasingly recognized that basic association measures
are insufficient to assess prognostic utility of biomarkers while newer
methods, that assess how well biomarkers assign patients to clinical
risk categories [3], yielded rather disappointing results [4,5].
Inflammatory molecules are among the most extensively studied
CVD biomarkers. For instance, a mildly raised C-reactive protein
(CRP) reflects a condition of chronic low-grade inflammation that
is considered one underlying cause of CVD development and
progression [6]. However, inconsistency exists regarding the ability
of CRP testing to improve risk assessment [7].
In the last decade, pathogenic models of CVD have moved to
consider the role of circulating cells potentially involved in
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bone marrow-derived cells able to migrate into the bloodstream
and participate in endothelial regeneration and angiogenesis
[9,10,11]. Many animal models confirm the protective effects of
EPCs on the cardiovascular system, and clinical studies show that
low levels of circulating EPCs associate with prevalent and
incident CVD [12,13,14]. Different phenotypes of circulating
progenitor cells (CPC), including EPCs, are thus emerging as novel
CVD biomarkers, which are also involved in disease pathogenesis
[15]. In survival analyses of longitudinal studies, a reduced CPC
count has been shown to independently predict cardiovascular
events in patients with CVD [13,16], chronic renal failure [17] or
metabolic syndrome [18], but it is still not clear if CPC count is
useful in the clinical setting for cardiovascular risk stratification.
Re-analysis of individual data from relevant prospective studies of
cardiovascular outcomes is emerging as a mean to address this
uncertainty in a rapid and cost-effective manner [19].
This study, resulting from the collaboration of 4 independent
research groups, tested the hypothesis that: i) adding CPC count to
a standard risk model for cardiovascular risk stratification of high-
risk individuals has a significant incremental predictive value; ii)
the relationship between CPC and incident cardiovascular events
is modified by inflammation and there is an interaction between
CPC and CRP levels in cardiovascular event prediction.
Methods
Participants
This study was conceived as a post-hoc re-analysis of crude
data from 4 previously published cohorts [13,16,17,18]. The
individual studies used for this pooled analysis were approved by
the respective local Institutional Ethical committees (University of
Saarland, J.W. Goethe University of Frankfurt, University
Hospital of Padova and Nagoya Kyoritsu Hospital), and written
informed consent was obtained from all subjects at time of the
study. Investigators of each source study provided patients’ data
on the basis of an agreed protocol and data scheme. The
following data were recorded for all patients: age, sex, smoking
habit, presence of cardiovascular risk factors, chronic renal failure
(CRF), prevalent CVD, and use of drugs. Twelve patients were
excluded because of missing at least one the above-mentioned
parameters. Shared definitions of cardiovascular risk factors were
used: diabetes mellitus was defined by fasting plasma glucose
$126 mg/dL or self-reported diabetes; smoking status was
defined as habitual smoking of $1 cigarette per day; hyperten-
sion was defined as systolic blood pressure $140 mmHg or a
diastolic blood pressure $90 mmHg, or the use of anti-
hypertensive drugs; dyslipidemia was defined as either a total
cholesterol concentration $200 mg/dL or a triglycerides con-
centration $200 mg/dl or a HDL cholesterol concentration of
less than 40 mg/dl in men and 50 mg/dl in women or the use
of statin/fibrates. CRF was defined as serum creatinine
.1.3 mg/dL for at least 6 months or if the patient was on
dialysis. CVD was defined as any of the following: a history of
previous myocardial infarction or stable angina, a significant
coronary artery diseases at angiography, peripheral arterial
disease (claudication, rest pain or ischemic foot ulcers), cerebro-
vascular disease (a history of stroke or carotid atherosclerosis),
presence of abdominal aortic aneurysm.
We also collected data on high sensitive C-reactive protein
(hsCRP) concentrations, which were categorized as high and low
according to an established cut-off (#3.0 mg/L or .3.0 mg/L)
[20]. hsCRP was measured using the turbidimetric method of
Roche Diagnostics [13,21] or Behring’s ultrasensitive LatexCRP
monotest [16], or the latex-enhanced high-sensitive CRP immu-
noassay (Nittobo Medical Co. Ltd) [22].
Circulating progenitor cell count
CPC were defined as circulating CD34+KDR+ cells in 2 studies
[13,16], or as circulating CD34+ cells in the other 2 studies
[17,18]. Given the different definitions and measures of CPC, we
adopted a strategy to render CPC count as much comparable as
possible, by expressing CPC as belonging to a tertile of the normal
distribution within each cohort. Thus, CPC count in the pooled
sample could be reported as high (3
rd tertile), intermediate (2
nd
tertile) or low (1
st tertile). A review of previous data suggest that
CD34+ cell level is more stable over time than CD34+KDR+ cell
level, which is more influenced by pharmacological treatment
[23,24].
Follow-up and definition of the endpoint
In all source studies, follow-up was conducted by telephone
contact, ambulatory visit or consultation of death registry.
Potential events were verified by analysis of medical records, such
as hospital charts and discharge letters. The main outcome
measure of this pooled study was a modified definition of major
adverse cardiovascular event (MACE). An incident MACE was
recorded if the patient matched one of the following conditions
during the follow-up period: cardiovascular (CV) death; non-fatal
acute myocardial infarction (AMI); hospitalization for unstable
angina or congestive heart failure (according to Framingham
criteria [25]); coronary or peripheral revascularization procedure;
angiographic evidence of restenosis after coronary revasculariza-
tion; major amputation due to peripheral ischemia, stroke or
transient ischemic attack. Event-free survival analyses were also
performed separately for CV death, non-fatal AMI, non-fatal
stroke and other CV events.
Statistical methods
Continuous data were reported as mean 6 standard error of the
mean (SEM), and categorical data as percentage. Event-free
survival was assessed with Cox proportional hazard analyses. Four
different sets of variables were constructed, to be entered into 4
models, respectively. In model 1 (reference model), sex, age,
cardiovascular risk factors, CRF, prevalent CVD and use of statins
and ACE inhibitors/ARBs were forced into the model. This
reference model was built to include all standard predictors of
cardiovascular events that could be retrieved from all source
studies. We included only those medications that were supposed to
influence both outcome and CPC, to be controlled for. In model 2,
variables of model 1 plus CPC were entered; in model 3, variables
of model 1 plus hsCRP were entered; in model 4, variables of
model 1 plus CPC and hsCRP were entered simultaneously.
Estimated risk functions were calculated using beta coefficients
from survival analyses and exponential transformation, similarly to
what described for generating the Framingham risk equation.
Risks estimated by Cox regressions were used to compare the
performance of the 4 models. Average C-statistics was calculated
as the area under ROC curve using either the logistic approach,
which ignores time-to-event, or Chambless and Diao’s method
[26] and Harrell’s method [27], which add time component to
area under curve estimation. Confidence intervals for C ˆ were
calculated based on Kendall’s t approximation as proposed by
Pencina et al.[28]. P-values for comparison between C ˆ were
computed from approximation to a normal distribution. Improve-
ment in model performance with addition of CPC and/or hsCRP
was also assessed by calculating the net reclassification improve-
ment (NRI) with pre-specified tertile categories of risk and the
Progenitor Cells and CV Risk
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described [3].
To explore the interaction between CPC and hsCRP levels in
relation to incident MACE, we divided patients into 6 groups
according to CPC tertiles and hsCRP,.3.0 mg/L. We then
compared unadjusted event rates using x
2 and adjusted relative
risks (RR) derived from Cox regression analysis of model 1 in these
categories of subjects. Rothman’s synergy index, a measure of
interaction as departure from additivity, was calculated as
previously described using adjusted RRs [29]. Confidence interval
of synergy index was calculated as suggested by Zou [30]. SPSS
versions 13.0 was used and statistical significance was accepted at
p,0.05.
Results
Patients’ characteristics
Clinical characteristics of the study patients are summarized in
Table 1. The study sample was representative of a high risk
population, as 76.3% of patients had CVD at baseline and 31.7%
had chronic renal failure. This is in compliance with a relatively
high incidence of MACE (331 events; 31.3% of subjects) over a
relatively short follow-up time (1.761.1 years). Events were
distributed as follows: 48 CV deaths, 19 non-fatal AMI, 19 non-
fatal stroke, and 245 other CV events.
Survival analysis
Cox proportional hazard analyses were performed to derive
different prediction models (Table 2). In model 1 (reference
model), hypertension, dyslipidemia, and prevalent CVD were
significant predictors of incident MACE. Both low CPC and raised
hsCRP (.3.0 mg/L), that were added respectively in models 2
and 3 were significant event predictors besides hypertension,
dyslipidemia and CVD. CPC count was a significant predictor of
incident MACE also in model 4, independently of hsCRP,
dyslipidemia and CVD. Patients were then divided into 2 groups
according to the presence/absence of prevalent CVD at baseline
and model 4 was run for both: CPC tertile was a significant inverse
event predictor in the CVD group, while there was a non-
significant trend for a higher event rate with decreasing CPC
tertile in the non-CVD group. Regarding event type, higher CPC
tertile in model 4 was an independent inverse predictor of CV
death (RR=0.59; p=0.007), non-fatal AMI (RR=0.50;
p=0.037) and other CV events (RR=0.81; p=0.009), while it
was not significantly associated with incident stroke/TIA
(RR=0.78; p=0.404). Figure 1 shows Kaplan-Meier curves of
incident events according to CPC tertiles (model 4) in the different
groups.
Linear risk functions were then calculated for each model using
regression coefficients of survival analyses and exponential
transformation, similarly to the equation used to derive the
Framingham 10-year risk. Discrimination and performance of the
risk estimates based on the 4 models were then assessed.
Effects of CPC on discrimination of survival models
Average C (C ˆ) was calculated using 3 methods. Logistic C ˆ,
which ignores time-to-event, was not significantly increased in
models 2, 3 and 4 as compared to model 1 (Figure 2A). Figure 2B
Table 1. Characteristics of study patients.
Characteristic Value
Age (years, mean 6 SEM) 63.160.4
Male gender (%) 64.2
Smoking (%) 24.3
Diabetes (%) 32.0
Hypertension (%) 70.7
Dyslipidemia (%) 56.8
hsCRP .3.0 mg/L (%) 39.1
Chronic renal failure/dialysis (%) 31.7
Prevalent CVD (%) 76.3
Statin use (%) 33.3
ACE inhibitor/ARB use (%) 51.4
doi:10.1371/journal.pone.0011488.t001
Table 2. Results of the Cox hazard-proportional analyses.
Variable Model 1 (reference) Model 2 (+CPC) Model 3 (+hsCRP) Model 4 (+CPC+hsCRP)
RR p RR p RR P RR p
Male gender 1.17 0.207 1.19 0.159 1.15 0.254 1.17 0.206
Age (for 10 yrs) 1.03 0.577 1.02 0.672 1.02 0.773 1.01 0.861
Smoke 0.94 0.668 0.92 0.551 0.93 0.611 0.92 0.512
Diabetes 1.18 0.151 1.14 0.266 1.18 0.154 1.13 0.290
Hypertension 1.45 0.022 1.38 0.046 1.45 0.023 1.36 0.061
Dyslipidemia 1.50 0.003 1.46 0.006 1.48 0.005 1.44 0.008
Chronic renal failure 0.98 0.894 0.97 0.814 0.96 0.782 0.95 0.708
Prevalent CVD 10.90 ,0.001 10.48 ,0.001 10.05 ,0.001 9.57 ,0.001
Use of statin 1.17 0.210 1.20 0.144 1.15 0.270 1.19 0.174
Use of ACEI/ARBs 0.96 0.767 0.97 0.817 0.98 0.838 0.98 0.900
CPC tertiles - - 0.77 ,0.001 - - 0.76 ,0.001
hsCRP.3.0 mg/L - - - - 1.52 ,0.001 1.57 ,0.001
All explanatory variables were entered simultaneously in the model. CPC was entered as a continuous variable and relative risk (RR) expressed per tertile increase. RR for
age is reported for each 10 yrs increase. ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers.
doi:10.1371/journal.pone.0011488.t002
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when CV death, non-fatal AMI and other CV events were
considered separately. Similarly, Chambless and Diao’s C ˆ, which
adds time component to the area under ROC curve estimation,
was not significantly higher when CPC count was entered in the
model, with our without hsCRP, as compared to model 1.
Harrell’s C ˆ, which is independent of calibration, showed no
significance discrimination improvement in model 2, 3 and 4, as
well. As expected [3], C ˆ was highest with the logistic approach and
lowest with Harrell’s method for all models (Table 3). These results
indicate that, on the basis of C-statistics, the addition of CPC did
not significantly improve discrimination of the new survival model
in comparison with a standard reference model.
Effects of CPC on improvement in model performance
We then assessed whether the models including CPC with or
without hsCRP yielded a better reclassification of patients in terms
of MACE prediction. To this end, the NRI was calculated based
on reclassification across tertiles of risk categories yielded by new
models in comparison to the reference model. Movement of
patients with incident MACE in higher risk categories and
Figure 1. Kaplan-Meier Curves. Different curves are plotted for patients belonging to the different CPC tertiles in the whole cohort, and in groups
of patients with or without prevalent CVD at baseline. Separate curves are also shown according to event type in whole cohort. Survival is corrected
for confounders entered in model 4. *significantly different versus the higher CPC tertile group.
doi:10.1371/journal.pone.0011488.g001
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categories were considered as correct reclassifications. As shown in
Table 4, in comparison to the reference model, inclusion of either
CPC or hsCRP was not associated with a statistically significant
NRI. Inclusion of both CPC and hsCRP in the model yielded
better reclassification of 6.5%, but still was not statistically
significant (p=0.13). Re-analysis by event type indicated that
inclusion of CPC measurement provided significant NRI for CV
death (model 2 vs model 1: NRI=18.6%, p=0.034; model 4 vs
model 1: NRI=22.7%, p=0.014), non-fatal AMI (model 2 vs
model 1: NRI=21.5%, p=0.043), and other CV events (model 2
vs model 1: NRI=6.5%, p=0.015; model 4 vs model 1:
NRI=11.9%, p,0.001), but not for non-fatal stroke.
Given that the NRI is highly dependent upon the pre-specified
categories of risk, we also calculated the integrated discrimination
improvement (IDI), which is a continuous assessment of
reclassification improvement, not based on risk categories. IDI
showed significant better discrimination by the models including
CPC with or without hsCRP as compared to the reference model.
Interestingly, there also was a significant IDI in the comparison of
model 4 with models 2 and 3, suggesting that the inclusion of both
CPC and hsCRP improved discrimination over the inclusion of
either CPC alone or hsCRP alone. Then, an interaction between
CPC and hsCRP was looked for.
Interaction between CPC and hsCRP
Patients were divided into groups according to their concentra-
tion of hsCRP (,.3.0 mg/L) and their belonging tertile of CPC
count. As shown in Figure 3, the risk of incident MACE across
CPC tertiles was different in the high versus low hsCRP
population: unadjusted event rates were significantly higher in
patients with a hsCRP.3.0 mg/L across all CPC tertiles. After
adjusting for age, sex, cardiovascular risk factors, CRF, prevalent
CVD and medications (model 1), a high hsCRP was significantly
associated with a higher relative risk (RR) of events in patients in
the lowest CPC tertile. The slope of the relationship between CPC
tertiles and RR of MACE was significantly higher in the high than
in the low hsCRP group (8.81 [95% C.I. 8.12–9.51] versus 12.70
[95% C.I. 12.07–13.33]; p,0.001). This trend was suggestive of
an interaction between CPC and hsCRP in relation to incident
MACE. Rothman’s synergy index, calculated as the excess risk in
patients with both low CPC and high hsCRP divided by the sum
of excess risk in patients either low CPC or high hsCRP, was
significantly different from zero (=1.709/[0.450+0.589]=1.64
[95% C.I. 1.04–2.60]; p=0.032), indicating a more-than-additive
interaction between CPC in the lower tertile and hsCRP
.3.0 mg/L in determining incident MACE.
Subsidiary analyses
Calibration analyses, performed using the Hosmer-Lemeshow
test, indicated no significant differences between observed and
expected event rates in all models and the x
2 value was lower in
models including CPC (model 2 an 4). Accordingly, observed
event rates across deciles of risk almost always fall within the 95%
confidence interval of expected event rates (calculated according to
the Poisson distribution), indicating good calibration (Figure 4).
Since the phenotype of CPC was inconsistent among studies
(CD34+KDR+ in 2 studies and CD34+ in 2 studies), we
performed distinct Cox regression analyses for subjects with
CD34+ or CD34+KDR+ cell counts. We found that both CPC
Figure 2. Discrimination analysis. Panel A shows ROC curves: logistic C ˆ is shown for each model. Panel B shows AUCs of logistic C ˆ with 95%
confidence intervals (bars) according to event type and model 1 to 4.
doi:10.1371/journal.pone.0011488.g002
Table 3. Performance of MACE prediction models using average C (C ˆ).
Model 1 (reference) Model 2 (+CPC) Model 3 (+hsCRP) Model 4 (+hsCRP+CPC)
Logistic C ˆ 0.687 (0.655–0.719) 0.707 (0.676–0.738) 0.695 (0.663–0.727) 0.716 (0.685–0.747)
Chambless and Diao’s C ˆ 0.691 (0.642–0.731) 0.707 (0.663–0.750) 0.695 (0.651–0.739) 0.716 (0.673–0.759)
Harrell’s C ˆ 0.631 (0.596–0.666) 0.635 (0.600–0.671) 0.644 (0.609–0.677) 0.648 (0.614–0.683)
95% confidence intervals reported in brackets.
doi:10.1371/journal.pone.0011488.t003
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model 4 (not shown), re-assuring us on the possibility to merge
together the cohorts. Further, when available data on
CD34+KDR+ cells of the Italian cohort [18] were merged to
data of the other 2 studies using CD34+KDR+ cell count (making
a total of 842 patients with a homogenous CPC definition), CPC
count was still an independent event predictor besides hsCRP in
model 4 (not shown), but improvement in C-statistics was minimal
(Logistic C ˆ: 0.730 [95% C.I.: 0.696–0.764] versus 0.729 [95%
C.I.: 0.695–0.763]; p=0.96. Chambless C ˆ: 0.718 [95% C.I.:
0.671–0.765] versus 0.715 [95% C.I.: 0.668–0.762]; p=0.93). In
2 studies data on CD34+ and CD34+KDR+ cells could be
retrieved. Thus, we compared categorization in tertiles using
either CD34+ or CD34+KDR+ cells and found that 61.2% of
patients were categorized in the same tertile by both definitions.
Moreover, only 5% of these patients were categorized in the lowest
tertile by one definition and in the higher tertile by the other
definition, suggesting a good correspondence between CPC
categorization in pooled cohorts.
Discussion
This pooled analysis represents the first attempt to determine the
ability of CPC count to improve cardiovascular risk stratification.
Based on C-statistics, inclusion of CPC in the risk equation provided
limited and non-significant improvement over and beyond a
standard model based on classic risk factors. However, a less
restrictive metric (the IDI) showed that the model including CPC
outperformed the reference model in terms of accuracy of even
prediction, independently and beyond the effect of hsCRP inclusion.
In each of the cohorts that compose the present study
population, CPC count was a significant independent predictor
of cardiovascular events [13,16,17,18], but none of the source
studies were well-powered to perform analysis of discrimination
improvement. Indeed, large clinical studies on CPC are not
available, because multicenter projects are hampered by the lack
of standardized methods for CPC quantification, and because
fresh blood samples for CPC determination must be processed
within a few hours, thus limiting the possibility to analyze stored
samples [31]. We tried to overcome these limitations by pooling
crude data from distinct yet similar studies. Our results show that a
low CPC count helps in identifying more patients at risk for future
MACE, for the first time providing some evidence in support of a
potential application of CPC count for cardiovascular risk
stratification in the clinical practice. CPC are protective against
the onset of CVD because they are involved in maintenance of a
healthy endothelial layer, by means of promoting re-endothelia-
lization of injured arteries [9]. Further, CPC are also protective
against CVD progression as they promote compensatory angio-
genesis in ischemic syndromes, thus limiting the extent of residual
ischemia [11]. Therefore, it is expected that a paucity of these cells
predispose to CVD onset or progression. Indeed, a reduced CPC
count is linearly associated with severity of CVD involvement [12].
Furthermore, low CPC were found to predict incident events
suggestive of CVD onset or progression in survival analyses of
different cohorts of patients [13,16,17,18]. Thus, CPC count is
revealing as a novel prototype of surrogate biomarkers for
cardiovascular risk, supported by both pathophysiological and
epidemiological evidence. In the present study, we addressed the
next important step in the evaluation pipeline of a putative
biomarker, that is the incremental value in quantitative risk
assessment over traditional risk factors [3]. Studying a high-risk
population, we first confirm that CPC count is independently
associated with incident events, and then looked at reclassification
improvement yielded by addition of CPC measure beyond
Table 4. Improvement of model performance.
NRI IDI
Model 2 vs Model 1 1.5% (p=0.71) 0.017 (p=0.0003)
Model 3 vs Model 1 23.4% (p=0.40) 0.011 (p=0.013)
Model 4 vs Model 1 6.3% (p=0.13) 0.029 (p,0.0001)
Model 3 vs Model 2 6.1% (p=0.16) 20.006 (p=0.38)
Model 4 vs Model 2 5.1% (p=0.17) 0.012 (p=0.008)
Model 4 vs Model 3 10.0% (p=0.008) 0.018 (p=0.0002)
Net reclassification improvement (NRI) is reported as the net percentage of
patients correctly reclassified by the new model across tertiles of MACE risk
categories. The integrated discrimination improvement (IDI), which can be
interpreted as a continuous version of NRI, is reported as absolute value.
doi:10.1371/journal.pone.0011488.t004
Figure 3. Interaction between CPC and hsCRP levels. Patients were divided into 6 groups according to CPC tertiles and high/low hsCRP. Left
panel shows unadjusted events rates (* significantly different in x
2 analysis versus hsCRP#3.0 mg/L). Right panel shows adjusted relative risks (RR)
from model 1 (Bars = SE; * significantly different versus hsCRP#3.0 mg/L).
doi:10.1371/journal.pone.0011488.g003
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metrics specifically designed to assess the clinical utility of one or
more biomarker(s) under scrutiny. Addition of CPC to a risk
model built on conventional risk factors had marginal and non-
significant effects on C statistics calculated using both the logistic
method and methods that take into account time to event. This is
not surprising, because C statistic is poorly sensitive to small
changes in predictive accuracy, such that even established risk
factors could be discarded as non-significant is some circumstances
[32]. Indeed, it is very uncommon that a single surrogate
biomarker improves C statistics when added to a well-fitted
reference model; notably, in previous studies, even combinations
of several biomarkers yielded modest changes in C ˆ when added to
a standard risk assessment [5,33]. Given the limitations of C
statistics, we also calculated the IDI, a newer metric that improves
when novel markers correctly assign individuals to higher or lower
probabilities of having events. The IDI for MACE prediction
improved significantly when either CPC or hsCRP were added to
the reference model, and improved further when both were added
together (Table 4). The NRI, a discrete version of IDI based on
upward or downward movement across pre-specified risk
categories, was significant for CV death, non-fatal AMI and other
CV risk, but not for the combined MACE. We used risk tertiles to
calculate the NRI given the impossibility to translate risk estimates
in the present population into the clinically-relevant standard 10-
year risk estimate. This might have affected results, since the NRI
is highly sensitive to pre-specified categories.
Cumulatively, our data suggest that CPC measure may add
incremental predictive value to standard risk assessment and that
this effect might be modulated by hsCRP levels. Accordingly, we
found a significant interaction between low CPC and high hsCRP
levels in predicting incident events. After statistical adjustment, the
excess risk of MACE in patients with both CPC in the lower tertile
and hsCRP.3.0 mg/L was higher than the sum of excess risks in
patients with either low CPC or high hsCRP, indicating a more-
than-additive interaction between the two risk biomarkers in
determining incident MACE. Biologically, this observation
suggests that reduced vascular repair and inflammation are two
distinct pathways of cardiovascular disease that synergize to
increase the likelihood of adverse outcomes.
Limitations
This study has limitations inherent to the pooling of data
coming from 4 different cohorts. First, the definition of CPC in the
Figure 4. Calibration of predictive models. Deciles of risk were calculated for each model. Observed and expected even rates are plotted against
deciles of risk. 95% confidence intervals (C.I.) for expected data according to the respective model were calculated according to the Poisson
distribution. Results of the Hosmer-Lemeshow x
2 test is shown for each model.
doi:10.1371/journal.pone.0011488.g004
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progeny of circulating (endothelial) progenitor cells is debated
[34]. In this pooled analysis, by transforming CPC counts into
tertiles, we could make data comparable and poolable, but
potential biological differences between CD34+ cells (measured in
2 studies [17,18]; n=430) and CD34+KDR+ cells (measured in
the other 2 studies [13,16]; n=627) might confound results. There
is evidence that CD34+ and CD34+KDR+ cell counts are
correlated each other and are subjected to consistent variations
[35], but the CD34+ cells form a more generic population of
progenitor cells, while CD34+KDR+ cells are primed to the
endothelial lineage and can be considered EPC [31,35]. Thus,
future studies should focus on a single CPC phenotype, but our
separated analyses for CD34+ and CD34+KDR+ cells showed
consistent results, suggesting that there is no definite evidence that
one phenotype is superior to the other(s) in terms of risk prediction.
Our analyses are limited by the need to categorize CPC count to
pool together the source studies; assessment of this surrogate
biomarker along the continuous scale may provide better results
and may offer the opportunity to define cutoffs. A second
limitation is that methods for hsCRP measurement were not
standardized among centers, and we simply could categorize
hsCRP levels as high or low according to the standard 3.0 mg/L
cutoff. Third, the original populations of patients are heteroge-
neous and the pooled cohort is mainly composed of high risk
individuals in primary and secondary prevention. It is generally
agreed that biomarkers perform better in high-risk than in low-risk
populations [36] and, in the present study, more significant results
were obtained in patients with baseline CVD. In addition, even if
we tried to harmonize the endpoint by using a modified definition
of MACE, event adjudication was not centralized.
Future directions
Results of the present study need to be replicated in a more
homogenous group of patients, yet large enough to allow statistical
power in the analysis of discrimination improvement. Finally, to
establish a definite causal link between reduced CPC and CVD
onset or progression, studies with a pathophysiology-focused
design are needed, such as mendelian randomization studies
and/or biomarker-guided targeted treatment studies [37,38].
Mendelian randomization studies could address polymorphisms
in the cd34 gene itself [39] or in the cxcl12 gene, encoding the
progenitor cell-regulating chemokine SDF-1a [40]. Interestingly,
CPC levels are also potentially modifiable and amenable to
pharmacological and non-pharmacological interventions. Many
drugs currently used in the treatment of CVD, including statins
and RAS blockers, have been shown to favorably modulate CPC
[9,41,42]. Lifestyle interventions, such as diet [43], weight loss
[44], exercise [45], and smoke cessation [46], have beneficial
effects on CPC, as well. Therefore, besides being a pathogenetic
actor, a disease biomarker and a prognostic indicator, CPC also
appear to be a potential therapeutic target. It remains to be
determined to what extent a therapeutic increase in CPC will
translate into an improvement of event-free survival.
Conclusions
Our data confirm that low CPC counts predicts adverse
cardiovascular outcomes independently of chronic low grade
inflammation, but synergistically with raised hsCRP levels.
Analysis of this pooled cohort also supports the potential use of
CPC count in cardiovascular risk stratification of high-risk
individuals, especially in combination with the measure of hsCRP.
A simplified CPC assessment by isolated CD34 expression analysis
may be a simple and cheap way of measuring this new surrogate
CV risk biomarker. Larger epidemiological and intervention
studies are needed to understand the causal relationships between
low CPC and CVD as well as the potential therapeutic
implications.
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